CN109563131A - 手性肽 - Google Patents

手性肽 Download PDF

Info

Publication number
CN109563131A
CN109563131A CN201780031671.6A CN201780031671A CN109563131A CN 109563131 A CN109563131 A CN 109563131A CN 201780031671 A CN201780031671 A CN 201780031671A CN 109563131 A CN109563131 A CN 109563131A
Authority
CN
China
Prior art keywords
amino acid
peptide reagent
tetramer peptide
tetramer
orn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780031671.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·D·莱文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kano Co Ltd
Original Assignee
Kano Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kano Co Ltd filed Critical Kano Co Ltd
Publication of CN109563131A publication Critical patent/CN109563131A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780031671.6A 2016-04-11 2017-04-10 手性肽 Pending CN109563131A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321168P 2016-04-11 2016-04-11
US62/321,168 2016-04-11
PCT/US2017/026869 WO2017180535A1 (en) 2016-04-11 2017-04-10 Chiral peptides

Publications (1)

Publication Number Publication Date
CN109563131A true CN109563131A (zh) 2019-04-02

Family

ID=60042852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031671.6A Pending CN109563131A (zh) 2016-04-11 2017-04-10 手性肽

Country Status (7)

Country Link
US (2) US10870678B2 (https=)
EP (1) EP3442990A4 (https=)
JP (1) JP2019523260A (https=)
CN (1) CN109563131A (https=)
AU (2) AU2017249218B2 (https=)
CA (1) CA3020393A1 (https=)
WO (1) WO2017180535A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981653A (zh) * 2020-01-17 2022-08-30 沃特世科技公司 用于肽图分析的低结合表面

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898653A4 (en) 2018-12-18 2022-08-24 Stealth BioTherapeutics Inc. ANALOGS TARGETING MITOCHONDRIAL DISEASES
US12404300B2 (en) 2018-12-18 2025-09-02 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US12215173B2 (en) 2019-08-07 2025-02-04 HUMANWELL PHARMACEUTICAL US, Inc. Kappa opioid receptor peptide amide ligands
EP4114429A2 (en) * 2020-03-06 2023-01-11 Allegro Pharmaceuticals, LLC Treatments for improving or lessening impairment of mitochondrial function
KR20230024419A (ko) 2020-06-25 2023-02-20 휴먼웰 파마슈티컬 유에스 의학적 장애 치료용 펩티드
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939027A (zh) * 2007-10-02 2011-01-05 Mdrna有限公司 用于递送核酸的脂肽
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
CN104822698A (zh) * 2012-07-11 2015-08-05 杰姆维克斯&凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
WO2008154373A1 (en) 2007-06-07 2008-12-18 Institute For Hepatitis And Virus Research 2-amino-2,7-dideoxy-alpha-d-glycero-d-gluco-heptopyranosyl inhibitors of positive sense single-stranded rna envelope viruses
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
JP5238297B2 (ja) 2008-03-04 2013-07-17 シャープ株式会社 認証方法および入力装置
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
PL2470191T3 (pl) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
AU2011207432A1 (en) 2010-01-25 2012-08-02 Cornell University Aromatic-cationic peptides and uses of same
EP3332795A1 (en) 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
JP2013532124A (ja) 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
JP6319738B2 (ja) 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
CA2831151A1 (en) 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
AU2012271691A1 (en) 2011-06-14 2014-01-16 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
WO2013059071A1 (en) 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
JP6317324B2 (ja) 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
CA2870200A1 (en) 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US20140034183A1 (en) 2012-07-31 2014-02-06 Viz Enterprises, Llc Cap assembly for dispensing a dispensable component and method of making and using the same
AU2013334788A1 (en) 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
WO2014165607A2 (en) 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
CA2919992C (en) 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015023680A1 (en) 2013-08-12 2015-02-19 Stealth Peptides International, Inc. Combination therapy for the treatment of ischemia-reperfusion injury
JP6480921B2 (ja) 2013-09-27 2019-03-13 コーネル ユニヴァーシティー コレステロール誘発性ミトコンドリア機能不全を治療するための芳香族カチオン性ペプチドの使用
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CA2932408A1 (en) 2013-12-02 2015-06-11 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
JP6626446B2 (ja) 2013-12-27 2019-12-25 ステルス バイオセラピューティックス コープ 薬学的に適切な芳香族カチオン性ペプチド
EP2913287B1 (en) 2014-02-26 2018-01-03 Otis Elevator Company Governor for controlling the speed of a hoisted object relative to a guide member
HK1231493A1 (zh) 2014-03-03 2017-12-22 Stealth Biotherapeutics Corp 药学上相关的芳香族阳离子肽
WO2016004441A1 (en) 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939027A (zh) * 2007-10-02 2011-01-05 Mdrna有限公司 用于递送核酸的脂肽
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
CN104822698A (zh) * 2012-07-11 2015-08-05 杰姆维克斯&凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981653A (zh) * 2020-01-17 2022-08-30 沃特世科技公司 用于肽图分析的低结合表面

Also Published As

Publication number Publication date
JP2019523260A (ja) 2019-08-22
AU2017249218B2 (en) 2020-08-27
US20190153032A1 (en) 2019-05-23
AU2020260489A1 (en) 2020-11-26
US10870678B2 (en) 2020-12-22
WO2017180535A1 (en) 2017-10-19
EP3442990A4 (en) 2019-12-18
CA3020393A1 (en) 2017-10-19
EP3442990A1 (en) 2019-02-20
US20200407395A1 (en) 2020-12-31
AU2017249218A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
CN109563131A (zh) 手性肽
JP2010510966A (ja) 合成ペプチドアミドおよびその二量体
CN108017636A (zh) 作为fxr调节剂的含氮杂环化合物
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
US20100105864A1 (en) Prophylactic or therapeutic agent for diarrhea
JP2020100628A (ja) 新規な細胞透過性サクシネート化合物
BR112020017385A2 (pt) Análogos de compstatina, métodos e seus usos médicos
US20240336597A1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
JP2023538807A (ja) 補体因子ｃ３の阻害剤及びそれらの医学的使用
US12150932B2 (en) Methods and compositions for delivery of biotin to mitochondria
EP0374097A2 (de) Verwendung von Peptidisosteren als retrovirale Proteasehemmer
KR20180109917A (ko) 헵시딘의 투여 방법
JP2021169531A (ja) 炎症を処置するための化合物および方法
CA3234071A1 (en) Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2019006692A1 (zh) 用于治疗、改善或预防神经系统相关病症的化合物及其用途
US20160333070A1 (en) Pro-angiogenic peptides and peptide conjugates
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
FR2778184A1 (fr) Composes a liaisons multiples antibacteriens nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
KR20150014910A (ko) 허혈-재관류계 질환의 치료 화합물
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
US20180148474A1 (en) Peptide derivative for regulating thymic stromal lymphoid protein-mediated signaling and pharmaceutical composition for preventing and treating allergy and asthma diseases comprising same
TW202233650A (zh) Masp抑制性化合物及其用途
US11879021B2 (en) Cyclic peptides and uses thereof
JP3874372B2 (ja) 制癌剤の効果増強剤
WO2013129660A1 (ja) オキシトシン受容体作動および／またはバソプレッシン受容体拮抗剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20201023

Address after: Massachusetts, USA

Applicant after: Akuyt therapeutics Co., Ltd

Address before: Massachusetts

Applicant before: Carnot, LLC

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190402

WD01 Invention patent application deemed withdrawn after publication